Fri, Mar 6, 2015, 9:17 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.


  • staccani staccani Oct 16, 2013 8:50 AM Flag

    Clearly the $55M price is way undervalued

    $70M in other assets not part of the sale
    +$55M for IP and inventory = $125M. The IP of any mature pharma is valued at 4-5 revenue, which equals to ca $150M. But this is a young biotech whose IP has not yet shown its full potential. I think we should be looking at least the double which is $300M + the 70M in other assets less debt, should leave at net value of $100M+ or $13 a share. Management and BOD are trying to protect their jobs, their salaries and bonuses and working against shareholders interests, als because they have done almost nothing to reduce absudely high fixed costs and at the same time granting tehmselves $200K bonuses for the successful completion of the sale. The application should be dismissed and a suit should be filed against mngt and BOD

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.00190.0000(0.00%)May 30 3:56 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.